Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine, and health food products. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.
Frequently asked questions
What sector does China Grand Pharmaceutical and Healthcare Holdings Ltd (0512) operate in?
China Grand Pharmaceutical and Healthcare Holdings Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is China Grand Pharmaceutical and Healthcare Holdings Ltd (0512) current stock price?
As of the latest data, China Grand Pharmaceutical and Healthcare Holdings Ltd stock price is HK$4.88, with a previous close of HK$4.74. China Grand Pharmaceutical and Healthcare Holdings Ltd gained HK$0.15 in the last trading session, representing a 3.06% increase.
What is China Grand Pharmaceutical and Healthcare Holdings Ltd (0512) current market capitalization?
China Grand Pharmaceutical and Healthcare Holdings Ltd market cap is approximately 17.09 billion.
What is China Grand Pharmaceutical and Healthcare Holdings Ltd (0512) EBITDA?
China Grand Pharmaceutical and Healthcare Holdings Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 1.47 billion.
Does China Grand Pharmaceutical and Healthcare Holdings Ltd (0512) pay dividends?
Yes. China Grand Pharmaceutical and Healthcare Holdings Ltd pays annual dividends with an annualized yield of 3.46% and an estimated annual payout of HK$0.17 per share.
When is the next ex-dividend date for China Grand Pharmaceutical and Healthcare Holdings Ltd (0512)?
The next ex-dividend date is scheduled for June 12, 2027.
When is China Grand Pharmaceutical and Healthcare Holdings Ltd (0512) next earnings report?
China Grand Pharmaceutical and Healthcare Holdings Ltd is expected to release its next earnings report on June 30, 2026.
What is China Grand Pharmaceutical and Healthcare Holdings Ltd (0512) beta (volatility) score?
China Grand Pharmaceutical and Healthcare Holdings Ltd has a beta of 0.671, indicating lower volatility than the overall market.